Analysts said blockbuster weight loss drugs like Wegovy are minimally profitable for retailers like Walmart – and may even come with slight margin headwinds.
, are developing their own GLP-1s in a bid to capitalize on a weight loss drug market that some analysts project could be worth $200 billion by 2030. An estimated 40% of U.S. adults are obese, making successful treatments a massive opportunity for drugmakers.
He said those drugs have high sales amounts per prescription, but emphasized that the increased volume of GLP-1s has a"minimal impact" on Rite Aid's gross profit. That's because GLP-1s like Wegovy and Ozempic are branded drugs with"very, very low gross margins," according to CFRA Research's Sundaram. In contrast, gross margins for generic drugs – the cheaper equivalents of branded medications – are 42.7% on average for pharmacies.
Brasil Últimas Notícias, Brasil Manchetes
Similar News:Você também pode ler notícias semelhantes a esta que coletamos de outras fontes de notícias.
Almost 100 Million Americans Eligible For New Weight Loss DrugA diabetes drug distributed under the brand name Wegovy could offer a suitable and beneficial weight loss treatment for some 93 million adults in the US, according to a new study.
Consulte Mais informação »
This week in tech: Analysts sweet on Nvidia; Tesla cuts prices again By Investing.comThis week in tech: Analysts sweet on Nvidia; Tesla cuts prices again
Consulte Mais informação »
Here's the trade on Nvidia ahead of earnings, according to analystsAhead of earnings Wednesday, analysts are weighing in on the forthcoming report and how to trade the earnings.
Consulte Mais informação »
Top Wall Street analysts pound the table on these 5 stocksTipRanks’ analyst ranking service pinpoints Wall Street’s best-performing stocks, including Amazon and Netflix.
Consulte Mais informação »
Crypto Analysts Split on Why Ether Outperformed Bitcoin During Last Week's SlideThe ether-bitcoin ratio rose more than 2% past week. The gain is inconsistent with its record of taking losses during bouts of risk aversion.
Consulte Mais informação »
Wall Street analysts take opposite views on Insulet following share price decline By Investing.comWall Street analysts take opposite views on Insulet following share price decline
Consulte Mais informação »